AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

NCT06196697 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL: Cadonilimab
BIOLOGICAL: Ivonescimab
DRUG: XELOX
DRUG: SOX

Sponsor

Harbin Medical University